GlassScriptPhysician profile
Judith A Adams
NPI 1457644759
$2,844.16
in general payments reported to CMS, 2019-2025
37 companies · $481 in 2025
The $481 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $122 · 2021: $637 · 2022: $468 · 2023: $492 · 2024: $362 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.20 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $435.94 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Minerva Surgical, INC | $242.95 | 2019-2022 | |
| Hologic Sales and Service, LLC | $233.23 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $202.46 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $145.95 | 2021-2024 | |
| Medtronic, INC. | $130.18 | 2022-2025 | Interstim, Truclear |
| Organon LLC | $129.38 | 2022-2024 | Nexplanon |
| Pfizer INC. | $118.37 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $116.80 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $91.21 | 2019-2022 | |
| Coopersurgical, INC. | $84.37 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Biogen, INC. | $81.03 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $76.12 | 2023-2025 | Veozah |
| Mylan Pharmaceuticals INC. | $75.74 | 2020-2022 | |
| Myovant Sciences INC. | $73.27 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $56.87 | 2021 | |
| Channel Medsystems, INC. | $54.34 | 2023 | |
| Evofem Biosciences, INC. | $39.33 | 2021-2023 | Phexxi |
| Daiichi Sankyo INC. | $35.40 | 2021 | |
| Roche Diagnostics Corporation | $35.23 | 2019 | |
| Abbott Laboratories | $35.07 | 2021 | |
| Exact Sciences Corporation | $31.73 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Shield Therapeutics INC | $30.67 | 2024 | |
| Alydia Health | $29.91 | 2021 | |
| Exeltis, USA INC. | $29.37 | 2021 | |
| Lupin INC. | $28.07 | 2020-2021 | |
| Meditrina | $27.92 | 2022-2025 | |
| Aspira Women'S Health INC | $21.72 | 2024 | Ova1 |
| Baxter Healthcare | $21.22 | 2024 | Perclot |
| Allergan, INC. | $20.12 | 2019 | |
| Ethicon US, LLC | $19.21 | 2025 | Stratafix, Dermabond Prineo |
| Boston Scientific Corporation | $18.39 | 2019 | |
| Optumhealth Care Solutions, LLC | $17.00 | 2023 | Vivify Health Care Team Portal |
| Sage Therapeutics, LLC | $15.27 | 2022 | |
| Smith+Nephew, INC. | $13.61 | 2025 | "Acticoat 4"" X 4""", Pico 7, Pico 14 |
| Innovation Technologies INC | $13.36 | 2024 | Irrisept |
| Millicent US INC | $13.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.